Cargando…
A retrospective analysis of the safety and efficacy of low dose tacrolimus (FK506) for living donor liver transplant recipients
We sought to evaluate the efficacy and effects of low-dose tacrolimus (FK506) to recipients with living donor liver transplantation (LDLT). A total of 66 patients who underwent LDLT between 2001 and 2007 were enrolled in this study. According to different doses of tacrolimus, the recipients were ran...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editorial Department of Journal of Biomedical Research
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3721039/ https://www.ncbi.nlm.nih.gov/pubmed/23885270 http://dx.doi.org/10.7555/JBR.27.20130023 |
_version_ | 1782278031003353088 |
---|---|
author | Wu, Zhengshan Meng, Qingyang Xia, Yongxiang Zhang, Feng You, Wei |
author_facet | Wu, Zhengshan Meng, Qingyang Xia, Yongxiang Zhang, Feng You, Wei |
author_sort | Wu, Zhengshan |
collection | PubMed |
description | We sought to evaluate the efficacy and effects of low-dose tacrolimus (FK506) to recipients with living donor liver transplantation (LDLT). A total of 66 patients who underwent LDLT between 2001 and 2007 were enrolled in this study. According to different doses of tacrolimus, the recipients were randomly divided into two groups: the low-dose tacrolimus group (group A) and the normal-dose tacrolimus group (group B). The blood concentration of tacrolimus and its side effects including infection, hyperglycemia, hypertension, high blood creatinine and jaundice were monitored once a week at the perioperative period, and once a month thereafter. Besides, the survival rates of the recipients were analyzed at the 1- and 3-year time point after operation. Among these patients, no significant acute rejection was detected after LDLT. The incidences of infection, hyperglycemia, liver dysfunction and renal impairment in group A were markedly lower than those in group B. However, no significant differences were detected in the incidence of hypertension between the two groups. Moreover, the recipients in each group had a similar survival rate according to the results of 1- and 3-year follow-up. The incidence of side effects that associated with tacrolimus positively correlated with tacrolimus blood concentration. In conclusion, long-term and low-dose administration of tacrolimus is a safe and effective treatment for LDLT recipients. |
format | Online Article Text |
id | pubmed-3721039 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Editorial Department of Journal of Biomedical Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-37210392013-07-24 A retrospective analysis of the safety and efficacy of low dose tacrolimus (FK506) for living donor liver transplant recipients Wu, Zhengshan Meng, Qingyang Xia, Yongxiang Zhang, Feng You, Wei J Biomed Res Research Paper We sought to evaluate the efficacy and effects of low-dose tacrolimus (FK506) to recipients with living donor liver transplantation (LDLT). A total of 66 patients who underwent LDLT between 2001 and 2007 were enrolled in this study. According to different doses of tacrolimus, the recipients were randomly divided into two groups: the low-dose tacrolimus group (group A) and the normal-dose tacrolimus group (group B). The blood concentration of tacrolimus and its side effects including infection, hyperglycemia, hypertension, high blood creatinine and jaundice were monitored once a week at the perioperative period, and once a month thereafter. Besides, the survival rates of the recipients were analyzed at the 1- and 3-year time point after operation. Among these patients, no significant acute rejection was detected after LDLT. The incidences of infection, hyperglycemia, liver dysfunction and renal impairment in group A were markedly lower than those in group B. However, no significant differences were detected in the incidence of hypertension between the two groups. Moreover, the recipients in each group had a similar survival rate according to the results of 1- and 3-year follow-up. The incidence of side effects that associated with tacrolimus positively correlated with tacrolimus blood concentration. In conclusion, long-term and low-dose administration of tacrolimus is a safe and effective treatment for LDLT recipients. Editorial Department of Journal of Biomedical Research 2013-07 2013-06-13 /pmc/articles/PMC3721039/ /pubmed/23885270 http://dx.doi.org/10.7555/JBR.27.20130023 Text en © 2013 by the Journal of Biomedical Research. All rights reserved. |
spellingShingle | Research Paper Wu, Zhengshan Meng, Qingyang Xia, Yongxiang Zhang, Feng You, Wei A retrospective analysis of the safety and efficacy of low dose tacrolimus (FK506) for living donor liver transplant recipients |
title | A retrospective analysis of the safety and efficacy of low dose tacrolimus (FK506) for living donor liver transplant recipients |
title_full | A retrospective analysis of the safety and efficacy of low dose tacrolimus (FK506) for living donor liver transplant recipients |
title_fullStr | A retrospective analysis of the safety and efficacy of low dose tacrolimus (FK506) for living donor liver transplant recipients |
title_full_unstemmed | A retrospective analysis of the safety and efficacy of low dose tacrolimus (FK506) for living donor liver transplant recipients |
title_short | A retrospective analysis of the safety and efficacy of low dose tacrolimus (FK506) for living donor liver transplant recipients |
title_sort | retrospective analysis of the safety and efficacy of low dose tacrolimus (fk506) for living donor liver transplant recipients |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3721039/ https://www.ncbi.nlm.nih.gov/pubmed/23885270 http://dx.doi.org/10.7555/JBR.27.20130023 |
work_keys_str_mv | AT wuzhengshan aretrospectiveanalysisofthesafetyandefficacyoflowdosetacrolimusfk506forlivingdonorlivertransplantrecipients AT mengqingyang aretrospectiveanalysisofthesafetyandefficacyoflowdosetacrolimusfk506forlivingdonorlivertransplantrecipients AT xiayongxiang aretrospectiveanalysisofthesafetyandefficacyoflowdosetacrolimusfk506forlivingdonorlivertransplantrecipients AT zhangfeng aretrospectiveanalysisofthesafetyandefficacyoflowdosetacrolimusfk506forlivingdonorlivertransplantrecipients AT youwei aretrospectiveanalysisofthesafetyandefficacyoflowdosetacrolimusfk506forlivingdonorlivertransplantrecipients AT wuzhengshan retrospectiveanalysisofthesafetyandefficacyoflowdosetacrolimusfk506forlivingdonorlivertransplantrecipients AT mengqingyang retrospectiveanalysisofthesafetyandefficacyoflowdosetacrolimusfk506forlivingdonorlivertransplantrecipients AT xiayongxiang retrospectiveanalysisofthesafetyandefficacyoflowdosetacrolimusfk506forlivingdonorlivertransplantrecipients AT zhangfeng retrospectiveanalysisofthesafetyandefficacyoflowdosetacrolimusfk506forlivingdonorlivertransplantrecipients AT youwei retrospectiveanalysisofthesafetyandefficacyoflowdosetacrolimusfk506forlivingdonorlivertransplantrecipients |